Ninnion

Ninnion is a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics for a number of indications including brain injury, inflammation, chronic pain and addiction.

Ninnion Therapeutics

Ninnion is building a fully integrated pharmaceutical psychedelics eco-system leveraging the latest AI drug discovery, in-house development, cGMP manufacturing, commercialization, patient clinics and a speciality pharmacy distribution network designed for the next frontier of psychedelic medicine.

The company has begun the development of NIN-S119, a proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke. NIN-S119 will be used in conjunction with physical/occupational therapy to potentiate the ability to form new neuronal connections (synapses) and strengthen the connectivity of remaining brain cells engaged during therapy.

“Ninnion leverages the power of AI Drug Discovery to deliver the future of novel psychedelic drug therapies optimized to restore functionality and enhance the lives of patients suffering from stroke, brain injury, chronic pain, inflammation, and addiction.”